IP Library › Granted Patent US 12,342,800
Granted Patent B2
US 12,342,800 · App. 17/030,995 · Granted Jul 1, 2025

Immunodeficient non-human animal

Inventors: Yuelei Shen (Beijing, CN); Yang Bai (Beijing, CN); Meiling Zhang (Beijing, CN); Jiawei Yao (Beijing, CN); Rui Huang (Beijing, CN); Yanan Guo (Beijing, CN)
A01K67/0276A01K67/0275C07K14/7155A01K67/0271A01K2207/12A01K2217/075A01K2217/15A01K2227/105A01K2267/0331A61K49/0008C12N2310/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,342,800
App. No.
17/030,995
Granted
Jul 1, 2025
Kind
B2
Abstract

The present disclosure relates to the genetically modified non-human animals that have a disruption at the endogenous CD132 gene (e.g., CD132 knockout), and methods of use thereof

Claims (51)

1. A genetically-modified non-human animal or a progeny thereof, whose genome comprises a disruption in the animal's endogenous CD132 gene, wherein the animal after being engrafted with human hematopoietic stem cells or peripheral blood cells is capable of developing a human immune system that has the following characteristics:

(a) the percentage of human CD45+ cells is greater than 70% of leukocytes of the animal;

(b) the percentage of human CD3+ cells is greater than 45% of leukocytes in the animal; and

(c) the percentage of human CD19+ cells is greater than 20% of leukocytes in the animal, wherein the disruption in the animal's endogenous CD132 gene comprises deletion of more than 150 nucleotides in exon 1, deletion of the entirety of intron 1, exon 2, intron 2, exon 3, intron 3, exon 4, intron 4, exon 5, intron 5, exon 6, intron 6, exon 7, intron 7, and deletion of more than 250 nucleotides in exon 8, wherein the animal is a NOD/scid mouse.

2. The animal of claim 1 , wherein the animal is homozygous with respect to the disruption of the endogenous CD132 gene.

3. The animal of claim 1 , wherein the animal does not express a functional CD132 protein or a functional interleukin-2 receptor.

4. The animal of claim 1 , wherein the animal has one or more of the following characteristics:

(a) the percentage of T cells (CD3+ cells) is less than 2% of leukocytes in the animal;

(b) the percentage of B cells (CD3−CD19+ cells) is less than 0.1% of leukocytes in the animal;

(c) the percentage of NK cells ( CD3−CD49b+ cells) is less than 2% of leukocytes in the animal;

(d) the percentage of CD4+ T cells is less than 0.5% of T cells;

(e) the percentage of CD8+ T cells is less than 0.5% of T cells;

(f) the percentage of CD3+CD4+ cells, CD3+CD8+ cells, or CD3−CD19+ cells is less than 1% of leukocytes in the animal; and

(g) the percentage of T cells, B cells, and NK cells is less than 5% of leukocytes in the animal.

5. The animal of claim 1 , wherein the animal has an enhanced engraftment capacity of exogenous cells relative to a NOD/scid mouse.

6. The animal of claim 1 , wherein the animal has one or more of the following characteristics:

(a) the animal has no functional T-cells and/or no functional B-cells;

(b) the animal exhibits reduced macrophage function relative to a NOD/scid mouse;

(c) the animal exhibits no NK cell activity; and

(d) the animal exhibits reduced dendritic function relative to a NOD/scid mouse.

7. The animal of claim 1 , wherein the animal further comprises a disruption in the animal's endogenous Beta-2-Microglobulin (B2m) gene or a disruption in the animal's endogenous Forkhead Box N1 (Foxn1) gene.

8. A method of determining effectiveness of an agent or a combination of agents for the treatment of cancer, comprising:

engrafting tumor cells to the animal of claim 1 , thereby forming one or more tumors in the animal;

administering the agent or the combination of agents to the animal; and

determining the inhibitory effects on the tumors.

9. The method of claim 8 , wherein before engrafting the tumor cells to the animal, human peripheral blood cells (hPBMC) or human hematopoietic stem cells are injected to the animal.

10. A method of producing an animal comprising a human hemato-lymphoid system, the method comprising:

engrafting a population of cells comprising human hematopoietic cells or human peripheral blood cells into the animal of claim 1 .

11. The method of claim 10 , wherein the human hemato-lymphoid system comprises human cells selected from the group consisting of hematopoietic stem cells, myeloid precursor cells, myeloid cells, dendritic cells, monocytes, granulocytes, neutrophils, mast cells, lymphocytes, and platelets.

12. The animal of claim 1 , wherein the percentage of human CD45+ cells is greater than 80% of leukocytes of the animal.

13. The animal of claim 1 , wherein the percentage of human CD3+ cells is at least 49% of leukocytes in the animal.

14. The animal of claim 1 , wherein the percentage of human CD19+ cells is greater than 25% of leukocytes in the animal.

15. The animal of claim 1 , wherein the disruption in the animal's endogenous CD132 gene consists of deletion of more than 150 nucleotides in exon 1, deletion of the entirety of intron 1, exon 2, intron 2, exon 3, intron 3, exon 4, intron 4, exon 5, intron 5, exon 6, intron 6, exon 7, intron 7, and deletion of more than 250 nucleotides in exon 8.

16. A genetically-modified, non-human animal whose genome comprises a disruption in the animal's endogenous CD132 gene, wherein the animal has one or more of the following characteristics:

(a) the percentage of T cells (CD3+ cells) is less than 2% of leukocytes in the animal;

(b) the percentage of B cells (CD3−CD19+ cells) is less than 0.1% of leukocytes in the animal;

(c) the percentage of NK cells (CD3−CD49b+ cells) is less than 2% of leukocytes in the animal;

(d) the percentage of CD4+ T cells is less than 0.5% of T cells;

(e) the percentage of CD8+ T cells is less than 0.5% of T cells;

(f) the percentage of CD3+CD4+ cells, CD3+CD8+ cells, or CD3−CD19+cells is less than 1% of leukocytes in the animal; and

(g) the percentage of T cells, B cells, and NK cells is less than 5% of leukocytes in the animal,

wherein the disruption in the animal's endogenous CD132 gene comprises

deletion of more than 150 nucleotides in exon 1,

deletion of the entirety of intron 1, exon 2, intron 2, exon 3, intron 3, exon 4, intron 4, exon 5, intron 5, exon 6, intron 6, exon 7, intron 7, and

deletion of more than 250 nucleotides in exon 8,

wherein the animal is a NOD/scid mouse.

17. The animal of claim 1 , wherein the animal undergoes irradiation before being engrafted with exogenous cells.

18. The animal of claim 1 , wherein the proportions of human leukocytes (hCD45+), human T cells (hCD3+) and human B cells (hCD19+) in leukocytes are analyzed using blood from the animal.

19. The animal of claim 1 , wherein the proportions of human leukocytes (hCD45+), human T cells (hCD3+) and human B cells (hCD19+) in leukocytes are analyzed at 10 weeks after being engrafted with exogenous cells.

20. The animal of claim 1 , wherein the disruption in the animal's endogenous CD132 gene is performed by CRISPR associated protein 9 (Cas9) with sgRNAs.

21. The animal of claim 1 , wherein the animal's genome has no additional genetic modifications other than the NOD/scid mutations and the disruption of the CD132 gene.

Assignments (2)
CHANGE OF NAME Recorded Jan 22, 2021
From: BEIJING BIOCYTOGEN CO., LTD
To: BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Reel/Frame 055087/0015 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2020
From: SHEN, YUELEI; BAI, YANG; ZHANG, MEILING; YAO, JIAWEI; HUANG, RUI; GUO, YANAN
To: BIOCYTOGEN LLC
Reel/Frame 053915/0028 →
Priority Claims (2)
CN 201710160547.1 · Mar 17, 2017 · national
CN 201810215804.1 · Mar 15, 2018 · national
Continuity (3)
Continuation 16435080 · Jun 7, 2019
Continuation PCTCN2018079365 · Mar 16, 2018
Related Publication 20210105982A1 · Apr 15, 2021
References Cited (136)
US 4683195A · Mullis et al. · 1987 [cited by applicant]
US 7145055B2 · Ito et al. · 2006 [cited by applicant]
US 7381560B2 · Anderson et al. · 2008 [cited by applicant]
US 10918095B2 · Shen et al. · 2021 [cited by applicant]
US 10973212B2 · Shen et al. · 2021 [cited by applicant]
US 20150106961A1 · Rojas et al. · 2015 [cited by applicant]
US 20160295844A1 · Herndler-Brandstetter et al. · 2016 [cited by applicant]
US 20160345549A1 · Gurer · 2016 [cited by applicant]
US 20190320631A1 · Shen et al. · 2019 [cited by applicant]
US 20190343097A1 · Shen · 2019 [cited by applicant]
US 20190373867A1 · Shen · 2019 [cited by applicant]
US 20210120790A1 · Shen · 2021 [cited by applicant]
US 20230058049A1 · Shen et al. · 2023 [cited by applicant]
CN 101809156 · 2010 [cited by applicant]
CN 103409468 · 2013 [cited by applicant]
CN 104039821 · 2014 [cited by applicant]
CN 104561095 · 2015 [cited by applicant]
CN 104904661 · 2015 [cited by applicant]
CN 105592695 · 2016 [cited by applicant]
CN 106119284 · 2016 [cited by applicant]
CN 106456749 · 2017 [cited by applicant]
CN 106755115 · 2017 [cited by applicant]
CN 107205368 · 2017 [cited by applicant]
CN 108467873 · 2018 [cited by applicant]
CN 108531487 · 2018 [cited by applicant]
CN 108588126 · 2018 [cited by applicant]
CN 109735498 · 2019 [cited by applicant]
WO WO200148020 · 2001 [cited by applicant]
WO WO2007033221 · 2007 [cited by applicant]
WO WO2010070047 · 2010 [cited by applicant]
WO WO2014172489 · 2014 [cited by examiner]
WO WO2012040207 · 2015 [cited by applicant]
WO WO2015042557 · 2015 [cited by applicant]
WO WO2015155904 · 2015 [cited by applicant]
WO WO2016089692 · 2016 [cited by applicant]
WO WO2016094679 · 2016 [cited by applicant]
WO WO2016168212 · 2016 [cited by applicant]
WO WO2016179399 · 2016 [cited by applicant]
WO WO2018001241 · 2018 [cited by applicant]
WO WO2018041118 · 2018 [cited by applicant]
WO WO2018041119 · 2018 [cited by applicant]
WO WO2018041120 · 2018 [cited by applicant]
WO WO2018041121 · 2018 [cited by applicant]
WO WO2018068756 · 2018 [cited by applicant]
WO WO2018086583 · 2018 [cited by applicant]
WO WO2018086594 · 2018 [cited by applicant]
WO WO2018113774 · 2018 [cited by applicant]
WO WO2018121787 · 2018 [cited by applicant]
WO WO2018177441 · 2018 [cited by applicant]
WO WO2019095358 · 2019 [cited by applicant]
DiSanto et al. (1995) P.N.A.S., vol. 92, 377-381. [cited by examiner]
Shultz et al. (2014) Cold Spring Harb. Protoc., vol. 7, 694-708 (pp. 1-24). [cited by examiner]
McIntosh et al. (2015) Stem Cell Reports, vol. 4, 171-180. [cited by examiner]
Cheah et al. (2001) vol. 19, 297-304. [cited by examiner]
Noguchi et al. (1993) J. Biol. Chem., vol. 268(18), 13601-13608. [cited by examiner]
DiSanto et al. (1994) Eur. J. Immunol., vol. 24, 3014-3018. [cited by examiner]
McDermott et al. (2010) Blood, vol. 115(2), 193-200. [cited by examiner]
Ansell et al., “A phase 1 study of TTI-621, a novel immune checkpoint inhibitor targeting CD47, in patients with relapsed refractory hematologic malignancies,” Blood, 2016, 1812. [cited by applicant]
Auerbach et al., “Establishment and Chimera Analysis of 129/SvEv- and C57BL/6-Derived mouse embryonic stem cell lines,” BioTechniques, 2000, 29:1024-1032. [cited by applicant]
Barclay et al., “The interaction between signal regulatory protein alpha (SIRPa) and CD47: structure, functino, and therapeutic target,” The Annual Review of Immunology, 2013, 32:25-50. [cited by applicant]
Barthold, “Genetically altered mice: phenotypes, no phenotypes, and Faux phenotypes,” Genetica, Sep. 2004, 122(1):75-88. [cited by applicant]
Brevini et al., “No shortcuts to pig embryonic stem cells,” Theriogenology, Sep. 2010, 74(4):544-550. [cited by applicant]
Buta et al. “Reconsidering pluripotency tests: do we still need teratoma assays?,” Stem Cell Res., Jul. 2013, 11(1):552-562. [cited by applicant]
Festing et al., “Revised nomenclature for strain 129 mice,” Mammalian Genome, 1999, 10:836. [cited by applicant]
Garcia-Arocena, “Same Mutation, Different Phenotype?,” The Jackson Laboratory, retrieved from URL <https://www.jax.org/news-and-insights/jax-blog/2014/november/same-mutation-different-phenotype#>, Nov. 11, 2014, 5 pages. [cited by applicant]
GenBank Accession No. AB012693.1, “Mus musculus mRNA for CD47, complete cds,” Mar. 30, 1998, 3 pages. [cited by applicant]
GenBank Accession No. BC062197.1, “Mus musculus signal-regulatory protein alpha, mRNA (cDNA clone MGC:70224 IMAGE:5368250), complete cds,” GenBank, Nov. 13, 2003, 4 pages. [cited by applicant]
GenBank Accession No. KJ903815.1, “Synthetic construct [cited by applicant]
GenBank Accession No. LN680437.1, “ [cited by applicant]
GenBank Accession No. NC_000003.12, “ [cited by applicant]
GenBank Accession No. NC_000020.11, “ [cited by applicant]
GenBank Accession No. NC_000068.7, “Mus musculus strain C57BL/6J chromosome 2, GRCm38.p6 C57BL/6J,” dated Jun. 24, 2020, 2 pages. [cited by applicant]
GenBank Accession No. NC_000082.6, “Mus musculus strain C57BL/6J chromosome 16, GRCm38.p6 C57BL/6J,” dated Jun. 24, 2020, 2 pages. [cited by applicant]
GenBank Accession No. NC_000086.7, “Mus musculus strain C57BL/6J chromosome X, GRCm38.p6 C57BL/6J,” dated Jun. 24, 2022, 2 pages. [cited by applicant]
GenBank Accession No. NM_000206.2, “ [cited by applicant]
GenBank Accession No. NM_001777.3, “ [cited by applicant]
GenBank Accession No. NM_007547.4, “Mus musculus signal-regulatory protein alpha (Sirpa), transcript variant 1, mRNA,” dated Jun. 13, 2021, 7 pages. [cited by applicant]
GenBank Accession No. NM_010581.3, “Mus musculus CD47 antigen (Rh-related antigen, integrin-associated signal transducer) (Cd47), transcript variant 4, mRNA,” dated Jun. 13, 2021, 4 pages. [cited by applicant]
GenBank Accession No. NM_013563.4, “Mus musculus interleukin 2 receptor, gamma chain (II2rg), transcript variant a, mRNA,” dated Jun. 1, 2021, 4 pages. [cited by applicant]
GenBank Accession No. NM_080792.2, “ [cited by applicant]
GenBank Accession No. NP_000197.1, “cytokine receptor common subunit gamma precursor [ [cited by applicant]
GenBank Accession No. NP_001768.1, “leukocyte surface antigen CD47 isoform 1 precursor [ [cited by applicant]
GenBank Accession No. NP_031573.2, “tyrosine-protein phosphatase non-receptor type substrate 1 isoform 1 precursor [Mus musculus],” dated Jun. 13, 2021, 4 pages. [cited by applicant]
GenBank Accession No. NP_034711.1, “leukocyte surface antigen CD47 isoform 4 precursor [Mus musculus],” dated Jun. 13, 2021, 3 pages. [cited by applicant]
GenBank Accession No. NP_038591.1, “cytokine receptor common subunit gamma isoform a precursor [Mus musculus],” dated Jun. 1, 2021, 3 pages. [cited by applicant]
GenBank Accession No. NP_542970.1, “tyrosine-protein phosphatase non-receptor type substrate 1 isoform 1 precursor [ [cited by applicant]
Gomez et al. “Derivation of cat embryonic stem-like cells from in vitro-produced blastocysts on homologous and heterologous feeder cells,” Theriogenology, Sep. 2010, 74(4):498-515. [cited by applicant]
Harms et al., “Mouse Genome Editing Using the CRISPR/Cas System,” Curr Protoc Hum Genetics, 2014, 15.7.1-15.7.27. [cited by applicant]
Heiman-Patterson et al., “Effect of genetic background on phenotype variability in transgenic mouse models of amyotrophic lateral sclerosis: A window of opportunity in the search for genetic modifiers,” Amyotrophic Late… [cited by applicant]
Hong et al., “Derivation and Characterization of Embryonic Stem Cells Lines Derived from Transgenic Fischer 344 and Dark Agouti Rats,” Stem Cells and Development, 2012, 21(9):1571-1586. [cited by applicant]
Huang et al., “Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy,” Journal of thoracic disease, Feb. 2017, 9(2):E168-E174. [cited by applicant]
Inagaki et al., “SHPS-1 regulates integrin-mediated cytoskeletal reorganization and cell motility,” The Embo Journal, 2000, 19(24):6721-6731. [cited by applicant]
International Preliminary Report on Patentability in International Appln. No PCT/CN2018/081628, dated Oct. 1, 2019, 6 pages. [cited by applicant]
International Preliminary Report on Patentability in International Appln. No PCT/CN2018/081629, dated Oct. 1, 2019, 6 pages. [cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/CN2018/079365, dated Sep. 26, 2019, 7 pages. [cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/CN2018/081628, dated Jun. 27, 2018, 12 pages. [cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/CN2018/081629, dated Jun. 27, 2018, 13 pages. [cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/CN2020/142546, dated Mar. 26, 2021, 14 pages. [cited by applicant]
Ito et al., NOD/SCID/ ycnull mouse: an excellent recipient mouse model for engraftment of human cells, Blood, 2002, 100(9):3175-3182. [cited by applicant]
Ivics et al., “Germline transgenesis in pigs by cytoplasmic microinjection of Sleeping Beauty transposons,” Nature Protocols, Apr. 2014, 9(4):810-827. [cited by applicant]
Legrand et al., “Functional CD47/signal regulatory protein alpha (SIRPa) interaction is required for optimal human T- and natural killer-(NK) cell homeostasis in vivo,” PNAS, 2011, 108(32):13224-13229. [cited by applicant]
Liu et al., “Is CD47 an innate immune checkpoint for tumor evasion?” Journal of Hematology & Oncology, Dec. 2017, 10(1):1-7. [cited by applicant]
Liu et al., “Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential,” PloS one, Sep. 21, 2015, 10(9):e013745, 23 pages. [cited by applicant]
Liu, “Strategies for designing transgenic DNA constructs,” Methods Mol. Biol., 2013, 1027:183-201. [cited by applicant]
Meng et al., “Optimized production of transgenic buffalo embryos and offspring by cytoplasmic zygote injection,” J. Animal Sci. and Biotech., Oct. 2015, 1-7. [cited by applicant]
Murata et al., “Autoimmune animal models in the analysis of the CD47-SIRPa signaling pathway,” Methods, 2013, pp. 1-6. [cited by applicant]
Murata et al., “The CD47-SIRPα signalling system: its physiological roles and therapeutic application,” The Journal of Biochemistry, Jun. 1, 2014, 155(6):335-344. [cited by applicant]
Paris et al. “Equine embryos and embryonic stem cells: defining reliable markers of pluripotency,” Theriogenology, Sep. 2010, 74(4):516-524. [cited by applicant]
Schilit et al., “Pronuclear Injection-Based Targeted Transgenesis,” Curr Protoc Hum Genet., Oct. 2016, 91(1):15.10.1-15.10.28. [cited by applicant]
Seiffert et al. “Signal-regulatory protein a (SIRPa) but not SIRPb is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34+ CD38− hematopoietic cells.” Blood, 2001, 97(9):27… [cited by applicant]
Shultz et al., “Humanized mice for immune system investigation: progress, promise, and challenges,” Nature Reviews Immunology, 2012, 12:786-798. [cited by applicant]
Strowig et al., “Transgenic expression of human signal regulatory protein alpha in Rag2-/-yc-/-mice improves engraftment of human hematopoietic cells in humanized mice,” PNAS, 2011, 108(32):1-6. [cited by applicant]
Tena et al., “Transgenic expression of human CD47 markedly increases engraftment in a murine model of pig-to-human hematopoietic cell transplantation,” Am J. Transplantation, 2014, 14(12):2713-2722. [cited by applicant]
Tong et al., “Production of p53 gene knockout rats by homologous recombination in embryonic stem cells,” Nature, Sep. 2010, 467(7312):211-213. [cited by applicant]
UniProt Accession No. P78324, “Tyrosine-protein phosphatase non-receptor type substrate 1,” Jun. 2, 2021, 12 pages. [cited by applicant]
West et al., “Genome Editing in Large Animals,” J. Equine Vet. Sci., Jun. 2016, 41:1-12. [cited by applicant]
Yanagita et al., “Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy,” JCI insight, Jan. 1, 2017, 2(1): 15 pages. [cited by applicant]
Zeng et al., “Generation and expression analysis of human [ [cited by applicant]
Cao et al., “Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain,” Immunity, 1995, 2(3):223-38. [cited by applicant]
Chang et al., “Modeling human severe combined immunodeficiency and correction by CRISPR/Cas9-enhanced gene targeting,” Cell Reports, 2015, 12:1668-1677. [cited by applicant]
Cheah et al., “Contemporary gene targeting strategies for the novice,” Mol. Biotechnol., 2001, 19(3):297-304. [cited by applicant]
DiSanto et al., “Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain,” PNAS, 1995, 92(2):377-381. [cited by applicant]
DiSanto et al., “The murine interleukin-2 receptor gamma chain gene: organization, chromosomal localization and expression in the adult thymus,” Eur. J. Innnnunol., 1994, 24:3014-3018. [cited by applicant]
Henthorn et al., “IL-2Ry gene microdeletion demonstrates that canine X-linked severe combined immunodeficiency is a homologue of the human disease,” Genomics, 1994, 23(1):69-74. [cited by applicant]
Hsu et al., “DNA targeting specificity of RNA-guided Cas9 nucleases,” Nat. Biotech., 2013, 31(9):827-832. [cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/CN2018/079365, dated Jun. 11, 2018, 11 pages. [cited by applicant]
Ishikawa et al., “Development of functional human blood and immune systems in NOD/SCID/IL2 receptor y chainnull mice,” Blood, 2005, 106(5):1565-1573. [cited by applicant]
Katano et al., “NOD-Rag2null IL-2Rynull mice: an alternative to NOG mice for generation of humanized mice,” Experimental animals, 2014, 63(3):321-330. [cited by applicant]
Liao et al., “IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation,” Current opinion of immunology, 2011, 23(5):598-604. [cited by applicant]
Mou et al., “A novel deletion mutation in IL2RG gene results in X-linked severe combined immunodeficiency with an atypical phenotype,” Immunogenetics, 2016, 69:29-38. [cited by applicant]
Noguchi et al., “Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor,” Science, 1993, 262(5141):1877-1880. [cited by applicant]
Ohbo et al., “Modulation of hematopoiesis in mice with a truncated mutant of the interleukin-2 receptor gamma chain,” Blood, 1996, 87(3):956-67. [cited by applicant]
Schultz et al. (2014) Cold Spring Harb. Protoc., vol. 7, 694-708 (pp. 1-24). [cited by applicant]
Shultz et al. “Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2Rγnull mice engrafted with mobilized human hemopoietic stem cells,” The Journal of Immunology, 2005, 174(10): 6477-6489. [cited by applicant]
Yin et al., “Delivery technologies for genome editing,” Nature Reviews Drug Discovery, 2017, 16(6):387-399. [cited by applicant]
Zhao et al., “Construction of severe combined immunodeficiency mice based on CRISPR/Cas9 technology,” Acta Laboratorium Animals Scientia Sinica, 2016, 24(4):339-343 (with English abstract only). [cited by applicant]